Evidence map›Paper›PMID 39997038›Full record

ArticleDiseases (Basel, Switzerland)2025

Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.

Ayrton Bangolo, Vignesh K Nagesh, Hadrian Hoang-Vu Tran, Brooke Sens, Daniel Elias, Behzad Amoozgar, Chase Tomasino, Izage Kianifar Aguilar, Charlene Mansour, Elizabeth Gagen and 15 more

Abstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Ayrton BangoloDepartment of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.ORCID 0000-0002-2133-2480
Vignesh K NageshDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Hadrian Hoang-Vu TranDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Brooke SensDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Daniel EliasRutgers New Jersey Medical School, Newark, NJ 07103, USA.
Behzad AmoozgarDepartment of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Chase TomasinoDepartment of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Izage Kianifar AguilarDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Charlene MansourRutgers New Jersey Medical School, Newark, NJ 07103, USA.
Elizabeth GagenDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Lili ZhangDepartment of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.ORCID 0000-0002-4771-4970
Sarvarinder GillDepartment of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Nisrene JebaraColumbia University School of Nursing, New York, NY 10032, USA.
Emma MadiganDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Christin CandelaDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Dohaa AminDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Peter GiuntaDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Shubhangi SinghDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Aman SiddiquiDepartment of Family Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Auda AudaDepartment of Family Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.ORCID 0009-0005-6422-3961
Paul PeejDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Timophyll Y H FongDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Simcha WeissmanDepartment of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Printhia Matshi LihauDepartment of Research and Innovation, Congolese National Cancer Control Center, Kinshasa, Democratic Republic of the Congo.
John Bukasa-KakambaDepartment of Endocrinology and Nuclear Medicine, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0003-1031-2326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntrahepatic cholangiocarcinoma (ICC), a malignancy originating from the epithelial cells of bile ducts, has shown a notable rise in its incidence over the years. It ranks as the second most frequent primary liver cancer after hepatocellular carcinoma. This study investigates how independent prognostic factors, specifically, age and tumor stage, interact to impact mortality in ICC patients. Furthermore, it examines the clinical features, survival rates, and prognostic indicators of ICC cases diagnosed between 2010 and 2017.

methodsUsing data from 5083 patients obtained from the Surveillance, Epidemiology, and End Results (SEER) database, this study evaluated demographic and clinical factors alongside overall mortality (OM) and cancer-specific mortality (CSM). Variables achieving a

resultsThe multivariate Cox proportional hazards analysis indicated higher OM in males (HR = 1.19, 95% CI: 1.12-1.26,

conclusionsThis retrospective analysis, utilizing data from the SEER database, provides new insights into mortality patterns in intrahepatic cholangiocarcinoma (ICC). This study identifies a significant interplay between two key prognostic factors, emphasizing their collective role in influencing mortality outcomes. Despite the predominance of advanced-stage diagnoses, our analysis underscores the substantial survival benefits associated with treatment interventions, with surgical procedures demonstrating the most pronounced impact. These findings highlight the importance of recognizing patients who may benefit from timely and intensive therapeutic strategies. Furthermore, the results underscore the need for future prospective randomized studies to deepen our understanding of these interactions in ICC, particularly as advancements in precision oncology continue to refine patient care.

Indexed as

age-related prognosisintrahepatic cholangiocarcinomamortality trendsSEER databasesurvival outcomestherapeutic interventionstumor stage

Identifiers

PMID39997038
PMCPMC11854301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.